✨ Breaking at #ACR24 KN5501 CAR-NK therapy is emerging as a safer and effective alternative to CAR-T for relapsed and refractory SLE patients. ✅ 50% DORIS remission ✅ 68.8% LLDAS (>6 months follow-up) ✅ No Grade ≥2 CRS or ICANS André Ribeiro

🔍 Why CAR-NK therapy works? 💥 Deep B-cell depletion + naïve B-cell reset. 💥 Complement normalization (C3, C4). 💥 Anti-dsDNA antibody reduction. ⚠️ Safety First! ⚠️ 💡 No severe CRS 💡 No ICANS 💡 No major infections André Ribeiro

Late breaking L17 #ACR24 More excitement in the cellular Rx field! N=22 refractory lupus open label (China) ✨CAR-NK (not T) ✨Allogenic! Avg F/up 7m, max 14m ⬇️ SLEDAI2K, PGA SRI4 ✅ DORIS remission 6m=50-%, 12m=💯 ✨With NO CRS >=2/ ICANS/ infections! Needs replication!

⁉️ CAR-NK therapy will redefine treatments for lupus ⁉️ ✅️ Targeted, very safe immune modulation with off-the-shelf availability. ☢️ As a CAR-T alternative, KN5501 represents a major breakthrough with further studies required to verify this data. André Ribeiro #ACR24

Late breaking L15 Phil Conaghan #ACR24 Phase 2 DBPCRCT novel neurotrophin NT3 ➖or + Ig = LEVI-4 Knee #OA n = 518, WOMAC >=20, KL >=2 N=518, 3 doses Achieved 1° outcome=change in WOMAC @ 17w stiffness, function, PGA ✅ Without concerning SAE, esp rapidly progressive OA

Late breaking L19 Alexei Grom #ACR24 Emapalumab: anti IFN y Ab, MAS in Still’s dz 💡Data pooled from 2 obs studies, n=49, mostly kids ✅ 1° outcome CR of ALL MAS criteria=53%, 69% if LDH excluded, 82% investigator determined remission, 95% survival 👎🏽TEAE = viral infections🦠

💡 New hope for severe/refractory #SLE: A-319 (CD3 x CD19 TCE) shows rapid and safe immune reset! ✅ Rapid B-cell depletion, autoantibody reduction, & organ improvement by W2 ✅ No CRS or ICANS observed 📊 Could this be a game-changer in SLE therapy? André Ribeiro #ACR24

#ACR24: The year of cell therapy in autoimmune diseases and redefining Tx paradigms! 🧬 Breakfree-1 CD19 CAR-T therapy shows sustained clinical remission in refractory #SLE and a safer profile. 🔬 Next-gen technology on the way. Stay tuned for more! André Ribeiro

Sarcoidosis is a granulomatous disorder that affects people of all racial and ethnic backgrounds. The pathogenesis of sarcoidosis remains incompletely understood. Learn more in the latest Interactive Medical Case: nej.md/3UQ4s6V

All-caps abstract text throw-down by Michelle Petri re:fractures in SLE 😆 I keep saying this; our obsesssion with vitamin d is not commensurate w/reality It's. The. Prednisone. #ACR24 Dr. John Cush Abstr#2679 #ACRBest

Not investing any time soon 😅 but this is a great summary!

So many options 🤩 But let's not forget that early diagnosis, close monitoring, improved adherence to treatment and minimising GC toxicity will probably have a larger impact in terms of absolute patient numbers and reach #LupusNephritis #Lupus

Shucks 😭 didn't make it! Oh well, keep trying💪 😂 #ACR24

4-year data from TREAT EARLIER The Lancet Rheumatology ⬇️ risk of seronegative RA for MTX arm (& 💉 IM triamcinolone) How about just the IM 💉 steroid ? Somehow not really convinced that treating with MTX makes sense? What do you think? 🤔 #RheumTwitter thelancet.com/journals/lanrh…

bhawna sirohi Dr. Neerja Bhatla AIIMS, New Delhi 🇮🇳 DGAFMS-MoD Congratulations to Dr. Bhatla from the AIIMS 1990 batch. We are proud to have been her students! Amit Verma Manjari Lahiri @SleepnLetSleep Vibhu Sharma

Day1 #APLAR2025 Focus on #lupus 🦋 The new TRM-SLE tinyurl.com/TRMSLE elegantly elucidated by Eric Morand focusing on indices that alter how patients #feel, #function or #survive And Laurent ARNAUD very energetic talk summarising current lupus trials Exciting times 🤩

And it’s a wrap for #APLAR2025 Well done team National University Health System 👏🏽👏🏽